Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake.

Pharmacogenomics - 1 Feb 2020

Ba Hai le, Mbatchi Litaty, Gattacceca Florence, Evrard Alexandre, Lacarelle Bruno, Blanchet Benoit, Ciccolini Joseph, Salas Sébastien

Abstract excerpt

A 53-year-old woman with papillary thyroid cancer treated with 800 mg sorafenib therapy rapidly experienced grade 3 toxicities. Dosing was reduced in a step-wise manner with several treatment discontinuations down to 200 mg every 2 days but severe toxicities continued. Plasma drug monitoring showed high exposure, even at low dose. Dosing was then further reduced at 200 mg every 3 days and tolerance was finally...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Pharmacogenomic Testing

Share to Pregnane X Receptor

Share to Sorafenib

Share to Thyroid Cancer, Papillary

Share to UDP-Glucuronosyltransferase 1A9

Source

Identifiers

PMID: 31967518
DOI: 10.2217/pgs-2019-0127

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake.PMID 31967518Read ↗

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.Semantic proximity Read ↗

OATP1B1 plays an important role in the transport and treatment efficacy of sorafenib in hepatocellular carcinomaSemantic proximity Read ↗

OATP1B1 Plays an Important Role in the Transport and Treatment Efficacy of Sorafenib in Hepatocellular Carcinoma.Semantic proximity Read ↗

Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.Semantic proximity Read ↗

Decitabine regulates the resistance of Hep3B to sorafenib through demethylationSemantic proximity Read ↗

Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.Semantic proximity Read ↗

Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.Semantic proximity Read ↗

SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.Semantic proximity Read ↗

Therapeutic Drug Monitoring of Sorafenib and Lenvatinib in Hepatocellular Carcinoma Patients – A Key to Personalised PharmacotherapySemantic proximity Read ↗

Therapeutic Drug Monitoring of Sorafenib and Lenvatinib in Hepatocellular Carcinoma Patients – A Key to Personalised PharmacotherapySemantic proximity Read ↗

Role of ATP-binding Cassette Transporters in Sorafenib Therapy for Hepatocellular Carcinoma: An OverviewSemantic proximity Read ↗

Proposal of a prediction model describing the metabolic interaction between warfarin and sorafenib using a population pharmacokinetic approach.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.